Hyperfractionated radiotherapy with cisplatin or cetuximab in advanced non-metastatic head and neck cancer, a phase II/III randomised study.

Trial Profile

Hyperfractionated radiotherapy with cisplatin or cetuximab in advanced non-metastatic head and neck cancer, a phase II/III randomised study.

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 03 Jun 2014

At a glance

  • Drugs Cetuximab (Primary) ; Cisplatin (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 21 Jun 2012 New trial record
    • 05 Jun 2012 Preliminary results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top